Zentalis Pharmaceuticals ZNTL 深 滬
已收盤 04-02 16:00:00 美东时间
2.63
+0.060
+2.33%
華盛通- 最 高2.70
- 今 開2.48
- 成交量 35.81万股
- 最 低 2.3901
- 昨 收 2.57
- 總市值 1.87亿
- 52周最高 3.95
- 市盈率 靜 --
- 換手率 0.50%
- 52周最低 1.13
- 委 比 -27.94%
- 總股本 7093.10万
- 歷史最高 87.19
- 量 比 0.59
- 振 幅 12.06%
- 歷史最低 1.01
- 每 手 1
- 風險率 0.56%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals授予两位新员工总计36,000股的非合格股票期权，期权授予价格为每股2.57美元，分四年 vesting。该计划旨在吸引新员工加入，期权授予符合纳斯达克上市规则。Zentalis专注于开发卵巢癌及其他肿瘤类型的创新疗法，其领先的WEE1抑制剂正在临床试验中。
04-01 21:00
美股大行评级 | 能源股再或大行青睐！康菲石油、雪铁龙、埃克森美孚、响尾蛇能源等获上调目标价；Unity评级分歧大，大摩、美银上调，富国银行下调
今日重点评级关注：花旗：维持Biomea Fusion"买入"评级，目标价从6美元升至7美元；Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.75美元升至8.25美元
03-30 11:49
Guggenheim Reiterates Buy on Zentalis Pharma, Maintains $6 Price Target
Guggenheim analyst Michael Schmidt reiterates Zentalis Pharma (NASDAQ:ZNTL) with a Buy and maintains $6 price target.
03-27 20:47
Zentalis Pharma Q4 EPS $(0.49) Misses $(0.44) Estimate.
Zentalis Pharma (NASDAQ:ZNTL) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.44) by 10.36 percent. This is a 25.76 percent increase over losses of $(0.66) per share from
03-27 04:39
Zentalis Pharmaceuticals GAAP EPS of -$1.91
Zentalis Pharmaceuticals press release (ZNTL): FY GAAP EPS of -$1.91. Cash, Cash Equivalents and Marketable Securities: As of December 31, 2025, the Company had cash, cash equivalents and marketable s...
03-27 04:33
Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026
Zentalis Pharmaceuticals announced two poster presentations at the 2026 AACR Annual Meeting, highlighting Azenosertib's potential as a combination therapy for Triple-Negative Breast Cancer and its biomarker-driven approach for Cyclin E1-positive ovarian cancer. Azenosertib, a WEE1 inhibitor, targets cell cycle checkpoints to induce cancer cell death. The company emphasizes Cyclin E1 protein overexpression as a predictive biomarker for poor progno...
03-17 20:30
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Zentalis Pharmaceuticals announced that its management team will participate in three upcoming investor conferences: Oppenheimer's 36th Annual Healthcare Life Sciences Conference (Feb. 25, 2026, virtual), TD Cowen's 45th Annual Health Care Conference (March 3, 2026, Boston), and Leerink Partners' Global Healthcare Conference (March 9, 2026, Miami). Live webcasts and recordings will be available on the company's website under the "Events & Present...
02-18 13:00
Vincent Vultaggio, PAO and PFO, Reports Sale of Zentalis Pharmaceuticals Common Shares
Vincent Vultaggio, PAO and PFO, Reports Sale of Zentalis Pharmaceuticals Common Shares Vincent Vultaggio, PAO and PFO of Zentalis Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created
02-05 09:28
Zentalis Pharmaceuticals to Participate in Guggenheim Emerging Outlook Biotech Summit
Zentalis Pharmaceuticals to Participate in Guggenheim Emerging Outlook Biotech Summit Zentalis Pharmaceuticals Inc. will participate in a fireside discussion during Guggenheim's Emerging Outlook: Biotech Summit 2026 on February 11th in New York, NY at 3:30 p.m. ET. Disclaimer: This news brief was cr
02-04 05:05
